AUTHORS
Xiaoyu Zhang, MD, Gang Li2, Lu Zhang3, Qiaoling MA4, Yi He, MD5, Zhiyong Yuan6, Erlie Jiang, MD7
AFFILIATIONS
1 State Key Laboratory of Experimental Hematology; Institute of Hematology & Blood Diseases Hospital; Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
2 State Key Laboratory of Experimental Hematology; Institute of Hematology & Blood Diseases Hospital; Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
3 Department of Radiation Oncology, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute & Hospital, Tianjin's Clinical Research Center for Cancer, National Clinical Research Center for Cancer, Tianjin, China
4 State Key Laboratory of Experimental Hematology; Institute of Hematology & Blood Diseases Hospital; Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
5 State Key Laboratory of Experimental Hematology; Institute of Hematology & Blood Diseases Hospital; Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
6 Department of Radiation Oncology, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute & Hospital, Tianjin's Clinical Research Center for Cancer, National Clinical Research Center for Cancer, Tianjin, China
7 State Key Laboratory of Experimental Hematology; Institute of Hematology & Blood Diseases Hospital; Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
ABSTRACT
Purpose: Acute myeloid leukemia (AML) patients with myeloid sarcoma (MS) presents a poor prognosis owing to resistance to conventional chemotherapy and limited tissue penetration. Current approaches, including systemic chemotherapy and irradiation, have yielded dismal efficacy, highlighting the critical need for novel therapeutic strategies. Stereotactic body radiotherapy (SBRT) has revolutionized localized treatment in solid tumors, delivering ablative radiation doses with millimeter-level precision over one to several fractions, thereby maximizing tumor control while sparing surrounding normal tissue. This approach has demonstrated robust efficacy with acceptable toxicity in multiple settings, including localized prostate cancer, non-small-cell lung cancer and hepatocellular carcinoma. However, the role of SBRT in myeloid malignancies remains poorly defined, particularly as a component of conditioning regimens before hematopoietic stem cell transplantation (HSCT). Here, we evaluated incorporating SBRT to conditioning regimen in this high-risk population. To our knowledge, this is the first such report on the use of SBRT in this clinical context.
Methods: This real-world analysis included MS patients aged ≥18 years receiving SBRT enhanced allo-HSCT at the Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences between November 2024 and January 2026. Diagnosis of extramedullary disease was confirmed by one of the following: pathological biopsy, cytology, or at least one imaging (including PET-CT, contrast-enhanced CT, or contrast-enhanced MRI). SBRT was delivered using the CyberKnife® robotic radiosurgery system (Accuray Inc.) with Xsight® skull tracking for image guidance. The gross tumor volume was delineated based on fused CT and MRI images, and a 1.25-mm expansion was applied to generate the planning target volume (PTV). A single fraction of 10-11 Gy was prescribed to the PTV and delivered at the beginning of conditioning regimen, followed by mitoxantrone liposome, thiotepa, busulfan, and cyclophosphamide. The study complied with the Declaration of Helsinki and was approved by the institutional review board.
Results: A total of 8 patients were included, with a median age of 34 years (range, 21-48). MS was documented in 6 patients who had concurrent AML and in 2 patients with isolated MS. The most frequently involved extramedullary site was brain (n=5), including cerebellar hemisphere(n=1), frontal lobe (n=2), temporal region (n=1) and multiple nodules in the left cerebral hemisphere(n=1), followed by sinonasal cavities(n=1), anterior mediastinum (n=1), and lumbosacral region (n=1). According to the ELN 2022 risk stratification, 3 patients were classified as adverse risk, including 1 TP53 mutation. At transplantation, extramedullary disease was assessed as non-remission (NR) by imaging in all patients. Meanwhile, 4 patients were in progressive AML (1 relapse and 3 refractory cases). Regarding comorbidities, 3 patients had Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) scores of ≥2, and only 2 had a score of ≥ 3.
Neutrophil and platelet engraftment took a median time of 16.5 and 18.5 days, respectively, without graft failure observed. Regimen-related toxicities included grade 3 nausea (n=1), and grade 3 mucositis (n=1). No VOD, TA-TMA and severe infections was reported. Grade 2 acute graft-versus-host disease (aGVHD) involving the skin occurred in only 1 patient. All patients achieved bone marrow CR on day +30. At 3 months after HSCT, six patients attained CR of extramedullary diseases, and the remaining 2 achieved PR. With a median follow-up of 186 days (range 116-471), 7 patients remained in CR, while 1 patient experienced bone marrow AML relapse on day 134 after transplantation.
Conclusion: Our cases series reported the safety and efficacy of incorporating SBRT into pretransplant conditioning. SBRT enhanced conditioning regimen represents a novel strategy for extramedullary AML, enabling rapid cytoreduction and facilitating subsequent allogeneic transplantation. To systematically evaluate the safety, feasibility, and efficacy of this approach, we have initiated a prospective clinical trial (NCT07456189), aiming to establish a personalized paradigm for these refractory extramedullary diseases.
DISCLOSURES
Xiaoyu Zhang, MD: No relevant conflicts of interest to declare.